RESEARCH & INNOVATION SHOWCASE Prof William Hope ADA – Antimicrobial Drug Accelerator – Compound to Clinic Streamlined package for early drug development and optimisation Innovative cell culture and hollow fibre models of bacterial and fungal disease Extensive laboratory animal programme for PK-PD Bioanalytical facility to GCP standards Advanced mathematical modelling techniques Strong links with Royal Liverpool NHS Trust Clinical Trials Unit Longstanding successful collaborations and networks in antimicrobial pharmacology A strong track record in publication Modelling the future of antimicrobial therapy! ADA will take your compound to the clinic ADA is unique as it has the skills, techniques and knowledge to take your compound through to clinic trial all in one place here at the University of Liverpool. ADA has a number of innovative in vitro cell culture and hollow fibre models to establish efficacy and appropriate dosages for your compound against a variety of organisms. ADA has the expertise to develop an intensive pre-clinical animal programme to determine the pharmacokinetics and pharmacodynamics of your compound ADA has a bioanalytical facility and a GCP laboratory for clinical samples. ADA uses advanced mathematical modelling techniques to determine the correct dosage and regimen to go into clinical trials. ADA has strong links with the Royal Liverpool clinical trials unit and has a past record of drug development with the clinical trials team in Liverpool. ADA has strong links with industry and regulatory leaders such as Prof John Rex. ADA is unique, experienced and ready to model the future of your antimicrobial compound. Come and see ADA at poster stand X7 for more information. Poster X7